Esteban Braggio
Mayo Clinic
Publications 170
Published on Aug 22, 2019in Leukemia9.94
Kristine Misund12
Estimated H-index: 12
(NTNU: Norwegian University of Science and Technology),
Niamh Keane2
Estimated H-index: 2
(National University of Ireland, Galway)
+ 21 AuthorsEsteban Braggio29
Estimated H-index: 29
(Mayo Clinic)
Published on Mar 14, 2019in Leukemia9.94
Elena Vendramini5
Estimated H-index: 5
Riccardo Bomben22
Estimated H-index: 22
+ 16 AuthorsGabriele Pozzato34
Estimated H-index: 34
(UniTS: University of Trieste)
Published on 2019in The New England Journal of Medicine70.67
Tait D. Shanafelt78
Estimated H-index: 78
Xin V. Wang1
Estimated H-index: 1
+ 7 AuthorsCong C. Zhang1
Estimated H-index: 1
Abstract Background Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients wi...
Published on Mar 1, 2019in American Journal of Hematology6.14
Hong Fang (Mayo Clinic), Kaaren K. Reichard15
Estimated H-index: 15
(Mayo Clinic)
+ 15 AuthorsJose F. Leis29
Estimated H-index: 29
(Mayo Clinic)
Published on Feb 1, 2019in Blood Cancer Journal7.89
Yuan Xiao Zhu10
Estimated H-index: 10
(Mayo Clinic),
Chang-Xin Shi14
Estimated H-index: 14
(Mayo Clinic)
+ 8 AuthorsPeter Leif Bergsagel73
Estimated H-index: 73
(Mayo Clinic)
To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-220, but not to Bortezomib. In three HMLCs (MM.1.SLenRes, KMS11LenRes and OPM2LenRes), CRBN abnormalities were found, including chromosomal deletion, point mutation, and low CRBN expression. The remai...
Published on Feb 1, 2019in Leukemia9.94
Santiago Barrio8
Estimated H-index: 8
Thorsten Stühmer15
Estimated H-index: 15
+ 18 AuthorsEllen Leich22
Estimated H-index: 22
(University of Würzburg)
Despite an increasing number of approved therapies, multiple myeloma (MM) remains an incurable disease and only a small number of patients achieve prolonged disease control. Some genes have been linked with response to commonly used anti-MM compounds, including immunomodulators (IMiDs) and proteasome inhibitors (PIs). In this manuscript, we demonstrate an increased incidence of acquired proteasomal subunit mutations in relapsed MM compared to newly diagnosed disease, underpinning a potential rol...